Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study

INTRODUCTION: Efficacy and safety of the Janus kinase (JAK) inhibitor upadacitinib (UPA) was evaluated in patients with psoriatic arthritis (PsA) through week 104 of the ongoing long-term extension of the phase 3 trial SELECT-PsA 1. METHODS: Exploratory analyses of all primary and secondary endpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: McInnes, Iain B., Kato, Koji, Magrey, Marina, Merola, Joseph F., Kishimoto, Mitsumasa, Haaland, Derek, Chen, Liang, Duan, Yuanyuan, Liu, Jianzhong, Lippe, Ralph, Wung, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569172/
https://www.ncbi.nlm.nih.gov/pubmed/36243812
http://dx.doi.org/10.1007/s40744-022-00499-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569172/
https://www.ncbi.nlm.nih.gov/pubmed/36243812
http://dx.doi.org/10.1007/s40744-022-00499-w

Ejemplares similares